keyword
https://read.qxmd.com/read/38653591/prognostic-significance-of-lymph-node-count-in-surgically-treated-patients-with-t-2-4-stage-nonmetastatic-adrenocortical-carcinoma
#1
JOURNAL ARTICLE
Anis Assad, Francesco Barletta, Reha-Baris Incesu, Lukas Scheipner, Simone Morra, Andrea Baudo, Cristina Cano Garcia, Zhe Tian, Sascha Ahyai, Nicola Longo, Felix K H Chun, Shahrokh F Shariat, Derya Tilki, Alberto Briganti, Fred Saad, Pierre I Karakiewicz
PURPOSE: The role of lymphadenectomy and the optimal lymph node count (LNC) cut-off in nonmetastatic adrenocortical carcinoma (nmACC) are unclear. METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database, surgically treated nmACC patients with T2-4 stages were identified between 2004 and 2020. We tested for cancer-specific mortality (CSM) differences according to pathological N-stage (pN0 vs. pN1) and two previously recommended LNC cut-offs (≥4 vs...
April 22, 2024: Urologic Oncology
https://read.qxmd.com/read/38633624/distinct-roles-of-cd244-expression-in-cancer-diagnosis-and-prognosis-a-pan-cancer-analysis
#2
JOURNAL ARTICLE
Zhenzhen Deng, Yuanhong Liu, Haiyan Zhou
The abnormal expression of tumor associated genes in pan-cancer is closely related to the clinicopathological features of distinct cancer types. Thus, identifying the role of specific genes in pan-cancer is needed for developing effective anti-cancer strategies. However, the function of CD244 in pan-cancer has not been fully understood. In this study, we explored the CD244 expression profile across 33 tumor types based on The Cancer Genome Atlas project, the Gene Expression Omnibus database, and other bioinformatics tools...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38626660/adrenocortical-cancer-in-the-real-world-a-comprehensive-analysis-of-clinical-features-and-management-from-the-turkish-oncology-group-tog
#3
JOURNAL ARTICLE
Hatime Arzu Yasar, Burak Yasin Aktas, Gokhan Ucar, Sema Sezgin Goksu, Irem Bilgetekin, Burcu Cakar, Abdullah Sakin, Ozturk Ates, Tugba Basoglu, Cagatay Arslan, Atike Gokcen Demiray, Semra Paydas, Irfan Cicin, Mehmet Ali Nahit Sendur, Nuri Karadurmus, Hakan Kosku, Aytuğ Uner, Perran Fulden Yumuk, Gungor Utkan, Umut Kefeli, Ozgur Tanriverdi, Havva Cinkir, Ozge Gumusay, Nazım Serdal Turhal, Serkan Menekse, Engin Kut, Ismail Beypinar, Teoman Sakalar, Hacer Demir, Emre Yekeduz, Saadettin Kilickap, Mustafa Erman, Yuksel Urun
INTRODUCTION: Adrenocortical carcinoma (ACC) is a rare yet highly malignant tumor associated with significant morbidity and mortality. This study aims to delineate the clinical features, survival patterns, and treatment modalities of ACC, providing insights into the disease's prognosis. MATERIALS AND METHODS: A retrospective analysis of 157 ACC patients was performed to assess treatment methodologies, demographic patterns, pathological and clinical attributes, and laboratory results...
March 15, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38617524/the-prognostic-biomarker-tpgs2-is-correlated-with-immune-infiltrates-in-pan-cancer-a-bioinformatics-analysis
#4
JOURNAL ARTICLE
Zujun Ding, Qing Ding, Hang Li
BACKGROUND: Tubulin polyglutamylase complex subunit 2 (TPGS2) is an element of the neuronal polyglutamylase complex that plays a role in the post-translational addition of glutamate residues to C-terminal tubulin tails. Recent research has shown that TPGS2 is associated with some tumors, but the roles of TPGS2 in tumor immunity remain unclear. METHODS: The research data were mainly sourced from The Cancer Genome Atlas. The data were analyzed to identify potential correlations between TPGS2 expression and survival, gene alterations, the tumor mutational burden (TMB), microsatellite instability (MSI), immune infiltration, and various immune-related genes across various cancers...
March 31, 2024: Translational Cancer Research
https://read.qxmd.com/read/38608694/cabozantinib-monotherapy-for-advanced-adrenocortical-carcinoma-a-single-arm-phase-2-trial
#5
JOURNAL ARTICLE
Matthew T Campbell, Vania Balderrama-Brondani, Camilo Jimenez, Gina Tamsen, Leonardo P Marcal, Jeena Varghese, Amishi Y Shah, James P Long, Miao Zhang, Joshua Ochieng, Cara Haymaker, Mouhammed Amir Habra
BACKGROUND: Adrenocortical carcinoma is a rare malignancy with poor response to systemic chemotherapy. Mitotane is the only approved therapy for adrenocortical carcinoma. Cabozantinib is a multikinase inhibitor approved in multiple malignancies. This is the first prospective trial to explore the anti-tumour activity, safety, and pharmacokinetic profile of cabozantinib in patients with advanced adrenocortical carcinoma. METHODS: This investigator-initiated, single-arm, phase 2 trial in adult patients (aged ≥18 years) with advanced adrenocortical carcinoma was done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA)...
April 9, 2024: Lancet Oncology
https://read.qxmd.com/read/38608692/mitotane-a-friend-or-a-foe-before-cabozantinib-treatment-in-adrenocortical-cancer
#6
JOURNAL ARTICLE
Margaret E Wierman
No abstract text is available yet for this article.
April 9, 2024: Lancet Oncology
https://read.qxmd.com/read/38605349/esco2-s-oncogenic-role-in-human-tumors-a-pan-cancer-analysis-and-experimental-validation
#7
JOURNAL ARTICLE
Yue Huang, Dapeng Chen, Yi Bai, Yamin Zhang, Zhiwen Zheng, Qingfeng Fu, Bocun Yi, Yuchen Jiang, Zhihong Zhang, Jianqiang Zhu
PURPOSE: Establishment of sister chromatid cohesion N-acetyltransferase 2 (ESCO2) is involved in the mitotic S-phase adhesins acetylation and is responsible for bridging two sister chromatids. However, present ESCO2 cancer research is limited to a few cancers. No systematic pan-cancer analysis has been conducted to investigate its role in diagnosis, prognosis, and effector function. METHODS: We thoroughly examined the ESCO2 carcinogenesis in pan-cancer by combining public databases such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), UALCAN and Tumor Immune Single-cell Hub (TISCH)...
April 11, 2024: BMC Cancer
https://read.qxmd.com/read/38580769/the-3d-in-vitro-adrenoid-cell-model-recapitulates-the-complexity-of-the-adrenal-gland
#8
JOURNAL ARTICLE
Serena Martinelli, Giulia Cantini, Arianna Pia Propato, Daniele Bani, Daniele Guasti, Patrizia Nardini, Laura Calosi, Tommaso Mello, Nicole Bechmann, Giovanna Danza, Fabio Villanelli, Letizia Canu, Mario Maggi, Massimo Mannelli, Elena Rapizzi, Michaela Luconi
The crosstalk between the chromaffin and adrenocortical cells is essential for the endocrine activity of the adrenal glands. This interaction is also likely important for tumorigenesis and progression of adrenocortical cancer and pheochromocytoma. We developed a unique in vitro 3D model of the whole adrenal gland called Adrenoid consisting in adrenocortical carcinoma H295R and pheochromocytoma MTT cell lines. Adrenoids showed a round compact morphology with a growth rate significantly higher compared to MTT-spheroids...
April 5, 2024: Scientific Reports
https://read.qxmd.com/read/38571632/estimation-of-the-tumor-size-at-cure-threshold-among-adult-patients-with-adrenocortical-carcinoma-a-populational-based-study
#9
JOURNAL ARTICLE
Yi Huang, Libo Liu, Qinghua Gan, Zefeng Shen, Yuhui Yao, Chengxiao Liao, Sihong Lu, Yitong Zou, Yaqiang Huang, Jianqiu Kong, Xinxiang Fan
BACKGROUND: The prognostic significance of tumor size with adrenocortical carcinoma (ACC) patients has not yet been thoroughly evaluated. Our objective was to investigate the influence of tumor size on prognostic value in adult ACC patients. METHODS: The Surveillance, Epidemiology and End Results Program (SEER) was employed to identify adult ACC patients who had been diagnosed from 2004 to 2015. The " X -Tile" program determined the optimal cutoff value of tumor size...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38539429/low-prkab2-expression-is-associated-with-poor-outcomes-in-pediatric-adrenocortical-tumors-and-treatment-with-rottlerin-increases-the-prkab2-level-and-inhibits-tumorigenic-aspects-in-the-nci-h295r-adrenocortical-cancer-cell-line
#10
JOURNAL ARTICLE
Alcides Euzebio Tavares Xavier, Luciana Chain Veronez, Luís Fernando Peinado Nagano, Carolina Alves Pereira Correa, Mirela Baroni, Milena Silva Ramos, Rosane de Gomes de Paula Queiroz, Carlos Augusto Fernandes Molina, José Andres Yunes, Silvia Regina Brandalise, Sonir Antonio Rauber Antonini, Luiz Gonzaga Tone, Elvis Terci Valera, Carlos Alberto Scrideli
Pediatric adrenocortical tumors (ACTs) are rare, highly heterogeneous neoplasms with limited therapeutic options, making the investigation of new targets with potential therapeutic or prognostic purposes urgent. The PRKAB2 gene produces one of the subunits of the AMP-activated protein kinase (AMPK) complex and has been associated with cancer. However, little is known about the role AMPK plays in ACTs. We have evaluated how PRKAB2 is associated with clinical and biological characteristics in 63 pediatric patients with ACTs and conducted in vitro studies on the human NCI-H295R ACC cell line...
March 8, 2024: Cancers
https://read.qxmd.com/read/38534453/personalized-driver-gene-prediction-using-graph-convolutional-networks-with-conditional-random-fields
#11
JOURNAL ARTICLE
Pi-Jing Wei, An-Dong Zhu, Ruifen Cao, Chunhou Zheng
Cancer is a complex and evolutionary disease mainly driven by the accumulation of genetic variations in genes. Identifying cancer driver genes is important. However, most related studies have focused on the population level. Cancer is a disease with high heterogeneity. Thus, the discovery of driver genes at the individual level is becoming more valuable but is a great challenge. Although there have been some computational methods proposed to tackle this challenge, few can cover all patient samples well, and there is still room for performance improvement...
March 14, 2024: Biology
https://read.qxmd.com/read/38532453/current-prospects-of-hereditary-adrenal-tumors-towards-better-clinical-management
#12
REVIEW
Akihiro Ohmoto, Naomi Hayashi, Shunji Takahashi, Arisa Ueki
Adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL) are two rare types of adrenal gland malignancies. Regarding hereditary tumors, some patients with ACC are associated with with Li-Fraumeni syndrome (LFS), and those with PPGL with multiple endocrine neoplasia type 2. Recent studies have expanded this spectrum to include other types of hereditary tumors, such as Lynch syndrome or familial adenomatous polyposis. Individuals harboring germline TP53 pathogenic variants that cause LFS have heterogeneous phenotypes depending on the respective variant type...
March 26, 2024: Hereditary Cancer in Clinical Practice
https://read.qxmd.com/read/38505747/the-mqrg-score-a-novel-prognostic-tool-for-adrenocortical-carcinoma-patients-based-on-mitochondrial-quality
#13
JOURNAL ARTICLE
Tao Chen, Yifan Wang, Xue Chen, Wenbin Zheng, Weiquan Guo, Qi Liang, Jing Wang, Zhongbiao Chen, Yiwen Zhou, Lijia Xiao
OBJECTIVES: Adrenal tumors are common, but adrenocortical carcinomas (ACCs) are a rare and challenging form of cancer to diagnose and manage.This study aimed to explore the critical role of mitochondrial quality in maintaining cellular function and the implications of the abnormal expression of mitochondrial metabolism-related proteins observed in ACC patients. We focused on identifying the connection between mitochondrial quality and the development of ACC at molecular and genomic levels...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38501000/comprehensive-analysis-of-adgre5-gene-in-human-tumors-clinical-relevance-prognostic-implications-and-potential-for-personalized-immunotherapy
#14
JOURNAL ARTICLE
Xiangjian Zhang, Xinxin Zhang, Qiuhui Yang, Ruokuo Han, Walaa Fadhul, Alisha Sachdeva, Xianbo Zhang
PURPOSE: The Adhesion G protein receptor E5 (ADGRE5) gene is involved in a wide range of biological functions in human tumors; however, its specific molecular mechanism and significance in the analysis of human tumors have not yet been determined. Here, we provide a comprehensive genomic architecture of ADGRE5 in the tumor immune microenvironment and its clinical relevance across a broad range of solid tumors. METHODS: In this study, we used publicly available bioinformatics databases, with a primary focus on The Cancer Genome Atlas (TCGA) database and GTEx data, to conduct a comprehensive analysis of the impact on patient prognosis associated with ADGRE5...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38496902/multidimensional-pan-cancer-analysis-of-hspa5-and-its-validation-in-the-prognostic-value-of-bladder-cancer
#15
JOURNAL ARTICLE
YaXuan Wang, Jinfeng Wang, Yang Liu, XiaoLin Wang, MingHua Ren
Endoplasmic reticulum (ER) stress-related genes are closely related to the occurrence, development, and immunotherapy response of tumors. This study provides a comprehensive assessment of HSPA5 from a pan-cancer perspective using multi-omics data. We analyzed the function of HSPA5 in multiple tumor types using multiple databases. Finally, immunohistochemistry was used to examine the relationship between HSPA5 expression in tissue microarrays from 100 patients with bladder cancer and the prognosis of patients with bladder cancer...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38482443/comprehensive-analysis-of-the-effects-of-the-cuprotosis-associated-gene-slc31a1-on-patient-prognosis-and-tumor-microenvironment-in-human-cancer
#16
JOURNAL ARTICLE
Guiqian Zhang, Ning Wang, Shixun Ma, Pengxian Tao, Hui Cai
BACKGROUND: Solute carrier family 31 (copper transporter), member 1 ( SLC31A1 ) is a key factor in maintaining intracellular copper concentration and an important factor affecting cancer energy metabolism. Therefore, exploring the potential biological function and value of SLC31A1 could provide a new direction for the targeted therapy of tumors. METHODS: This study assessed gene expression levels, survival, clinicopathology, gene mutations, methylation levels, the tumor mutational burden (TMB), microsatellite instability (MSI), and the immune cell infiltration of SLC31A1 in pan-cancer using the Tumor Immune Estimation Resource 2...
February 29, 2024: Translational Cancer Research
https://read.qxmd.com/read/38473262/the-efficacy-and-safety-of-immune-checkpoint-inhibitors-in-adrenocortical-carcinoma-a-systematic-review-and-meta-analysis
#17
REVIEW
Obada Ababneh, Alina Ghazou, Mohmmad Alawajneh, Saleh Alhaj Mohammad, Abdullah Bani-Hani, Nasr Alrabadi, Aditya Shreenivas
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of different malignancies. However, their efficacy in advanced adrenocortical carcinoma (ACC) remains uncertain. Thus, we conducted a systematic review and meta-analysis to summarize the efficacy and tolerability of ICIs in patients with advanced ACC. We searched PubMed, Scopus, and CENTRAL for studies that used ICIs in ACC. Studies with more than five patients were included in the meta-analysis of the objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and grade 3/4 adverse events...
February 23, 2024: Cancers
https://read.qxmd.com/read/38463201/surgical-management-of-metastatic-adrenocortical-carcinoma
#18
JOURNAL ARTICLE
Jesse E Passman, Wajid Amjad, Sara P Ginzberg, Jacqueline M Soegaard Ballester, Caitlin Finn, Heather Wachtel
INTRODUCTION: Adrenocortical carcinoma (ACC) is a notoriously aggressive cancer with a dismal prognosis, especially for patients with metastatic disease. Metastatic ACC is classically a contraindication to operative management. Here, we evaluate the impact of primary tumor resection and metastasectomy on survival in metastatic ACC. METHODS: We performed a retrospective cohort study of patients with metastatic ACC (2010-2019) utilizing the National Cancer Database...
January 2024: World Journal of Surgery
https://read.qxmd.com/read/38455785/adrenocortical-sarcomatoid-carcinoma-revealed-by-an-adrenal-incidentaloma-a-case-report
#19
Samia Bentaleb, Ghita Bourkadi, Hayat Aynaou, Houda Salhi
Sarcomatoid carcinoma of the adrenal gland represents an exceedingly unusual and highly aggressive form of adrenocortical carcinoma. Its diagnosis is challenging because of its dual histological components: epithelial and sarcomatoid. Most patients are diagnosed at a late stage and die within months of diagnosis. We report on a 51-year-old man who had adrenocortical sarcomatoid cancer. It was diagnosed as a unilateral left adrenal incidentaloma discovered on a CT scan carried out for abdominal pain. By means of this case, we will present the clinical, radiological, and histological profile of this tumor...
February 2024: Curēus
https://read.qxmd.com/read/38451242/circulating-cell-free-dna-based-biomarkers-for-prognostication-and-disease-monitoring-in-adrenocortical-carcinoma
#20
JOURNAL ARTICLE
Juliane Lippert, Gabrielle Smith, Silke Appenzeller, Laura-Sophie Landwehr, Alessandro Prete, Sonja Steinhauer, Miriam Asia, Hanna Urlaub, Yasir S Elhassan, Stefan Kircher, Wiebke Arlt, Martin Fassnacht, Barbara Altieri, Cristina L Ronchi
Adrenocortical carcinoma (ACC) is a rare aggressive cancer with heterogeneous behaviour. Disease surveillance relies on frequent imaging, which comes with significant radiation exposure. The aim of the study was to investigate the role of circulating cell-free DNA (ccfDNA)-related biomarkers (BM) for prognostication and monitoring of ACC. We investigated 34 patients with ACC and 23 healthy subjects (HS) as controls. ccfDNA was extracted by commercial kits and ccfDNA concentrations quantified by fluorimeter (BM1)...
March 7, 2024: European Journal of Endocrinology
keyword
keyword
53561
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.